TY  - JOUR
AU  - Beyer, Leonie
AU  - Nitschmann, Alexander
AU  - Barthel, Henryk
AU  - van Eimeren, Thilo
AU  - Unterrainer, Marcus
AU  - Sauerbeck, Julia
AU  - Marek, Ken
AU  - Song, Mengmeng
AU  - Palleis, Carla
AU  - Respondek, Gesine
AU  - Hammes, Jochen
AU  - Barbe, Michael T.
AU  - Onur, Özgür
AU  - Jessen, Frank
AU  - Saur, Dorothee
AU  - Schroeter, Matthias L.
AU  - Rumpf, Jost-Julian
AU  - Rullmann, Michael
AU  - Schildan, Andreas
AU  - Patt, Marianne
AU  - Neumaier, Bernd
AU  - Barret, Olivier
AU  - Madonia, Jennifer
AU  - Russell, David S.
AU  - Stephens, Andrew W.
AU  - Roeber, Sigrun
AU  - Herms, Jochen
AU  - Bötzel, Kai
AU  - Levin, Johannes
AU  - Classen, Joseph
AU  - Höglinger, Günter U.
AU  - Bartenstein, Peter
AU  - Villemagne, Victor
AU  - Drzezga, Alexander
AU  - Seibyl, John
AU  - Sabri, Osama
AU  - Brendel, Matthias
TI  - Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
JO  - European journal of nuclear medicine and molecular imaging
VL  - 47
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - FZJ-2020-01803
SP  - 2911–2922
PY  - 2020
AB  - PurposeSecond-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG).MethodsTwenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer’s disease, progressive supranuclear palsy, corticobasal syndrome, multi-system atrophy, Parkinson’s disease, multi-system atrophy, Parkinson's disease, frontotemporal dementia) and received a dynamic [18F]PI-2620 tau-PET (0–60 min p.i.) and static [18F]FDG-PET (30–50 min p.i.). Regional standardized uptake value ratios of early-phase images (single frame SUVr) and the blood flow estimate (R1) of [18F]PI-2620-PET were correlated with corresponding quantification of [18F]FDG-PET (global mean/cerebellar normalization). Reduced tracer uptake in cortical target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three more and three less experienced readers. Spearman rank correlation coefficients were calculated between early-phase [18F]PI-2620 tau-PET and [18F]FDG-PET images for all cortical regions and frequencies of disagreement between images were compared for both more and less experienced readers.ResultsHighest agreement with [18F]FDG-PET quantification was reached for [18F]PI-2620-PET acquisition from 0.5 to 2.5 min p.i. for global mean (lowest R = 0.69) and cerebellar scaling (lowest R = 0.63). Correlation coefficients (summed 0.5–2.5 min SUVr & R1) displayed strong agreement in all cortical target regions for global mean (RSUVr 0.76, RR1 = 0.77) and cerebellar normalization (RSUVr 0.68, RR1 = 0.68). Visual interpretation revealed high regional correlations between early-phase tau-PET and [18F]FDG-PET. There were no relevant differences between more and less experienced readers.ConclusionEarly-phase imaging of [18F]PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a dual time-point protocol for tau-PET imaging could supersede additional [18F]FDG-PET imaging by indexing both the distribution of tau and the extent of neuronal injury.
LB  - PUB:(DE-HGF)16
C6  - pmid:32318783
UR  - <Go to ISI:>//WOS:000528092500001
DO  - DOI:10.1007/s00259-020-04788-w
UR  - https://juser.fz-juelich.de/record/875100
ER  -